

SmartCella publishes its 2024 Annual Report

Following yesterday's invitation to the Annual General Meeting, SmartCella Holding AB ("SmartCella") today publishes its inaugural formal Annual Report. The English version is an extended, unaudited translation of the official 2024 Annual Report in Swedish. Both reports are available at www.smartcella.com/shareholders.

SmartCella has made significant commercialization and scientific progress in 2024. In parallel, the company has focused on strengthening its infrastructure in key areas to enable scaling for continued growth and development.

In his statement, Christian Kinch, founder and Chairperson, emphasizes: "We are driven by a powerful mission: to bring cutting-edge delivery solutions and life-changing treatments to patients in need. We put patients first, offering hope by tackling some of the world's most pressing health challenges. At the same time, we put science first, because true medical breakthroughs are born from innovation. By embracing entrepreneurship and visionary thinking, we are building SmartCella into a company that delivers both transformative healthcare solutions and long-term value for our shareholders."

In his reflections on the year, Niklas Prager, SmartCella CEO, highlights: "With the enhanced experiences and skills of our Management Team, we have raised our operational standards. In Finance, we have built a team and processes that meet the demands of a listed company. Additionally, we have implemented an ERP system and enacted a comprehensive suite of policies, ensuring robust governance, control and structure. We also strengthened our technical, quality, and manufacturing capabilities and initiated full-scale GMP-production of heart cells in our Tullinge facility. This infrastructure will also provide scaleup and production for our other clinical assets in the future."

The SmartCella Annual 2024 report is published in Swedish, with a translation into English. In the event of any discrepancies between the language versions, the Swedish version shall prevail.

Contact

Niklas Prager, CEO +46 76 811 77 44

Nina Nornholm, Head of Communication +46 708 550 356

About SmartCella

SmartCella is a global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development. Founded in 2014, the company is built on globally renowned science and research from Karolinska Institutet in Sweden. SmartCella combines novel delivery platforms, such as the Extroducer® (an endovascular delivery device that enables direct injection to hard-to-reach organs and tumors), with cutting-edge development and manufacturing of cell therapies. The company operates in two business segments: Targeted Delivery and Regenerative Medicines. The Extroducer has been FDA-cleared for use in abdominal organs and is a clinical-stage investigational device for the heart.

The international team consists of scientists, visionary innovators, and experienced business leaders, all dedicated to shaping the future of targeted therapies and delivering life-changing treatments to patients.

Read more on www.smartcella.com
Follow SmartCella on [LinkedIn](#)